ID   K562/DAC
AC   CVCL_WI19
DR   Wikidata; Q94335820
RX   PubMed=30793488;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:50131; 5-aza-2'-deoxycytidine (Decitabine).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 29-06-23; Version: 10
//
RX   PubMed=30793488; DOI=10.1111/jcmm.14221;
RA   Wen X.-M., Zhang T.-J., Ma J.-C., Zhou J.-D., Xu Z.-J., Zhu X.-W.,
RA   Yuan Q., Ji R.-B., Chen Q., Deng Z.-Q., Lin J., Qian J.;
RT   "Establishment and molecular characterization of decitabine-resistant
RT   K562 cells.";
RL   J. Cell. Mol. Med. 23:3317-3324(2019).
//